TrialInternational journal of clinical oncology2026
Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.
Chika Nitani et al.PubMed ↗Publisher ↗
No numbers read from the abstract.